Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Dexibuprofen is a pharmacologically active enantiomer of the racemic ibuprofen used to treat pain and inflammation. Pharmacokinetically and clinically it behaves like ibuprofen itself (Yoon 2008, Sádaba 2006). Oral administration in three daily doses.
On latest update no published data about breastfeeding were found.
Its high binding to plasma proteins makes it unlikely to be excreted in breast milk in significant quantities.
As it is an enantiomer of ibuprofen, with similar pharmacokinetic characteristics, it is considered to have similar compatibility with breastfeeding.